If Acadia moving forward with NNZ-2591 could boost Neuren's share price then surely it could boost Acadia's also - Acadia stands to make more from NNZ-2591 for Retts & Fragile X than Neuren. It seems like "cutting off your nose to spite your face" for Acadia to deliberately delay developing NNZ-2591 just to keep Neuren low for a takeover. And who would they be benefiting with such a strategy - themselves or every other potential suitor?
In theory Acadia also have little control over whether they can successfully acquire Neuren. But they do have control over whether they can develop NNZ-2591 for Retts & Fragile X. The market potential for Fragile X (particularly with the promise of NNZ-2591) is many multiples that of Daybue and the patent expiry is coming closer every year. NNZ-2591 for Retts could arguably increase the market penetration by 50% - meaning the increased sales could pay for the trial costs in just one year on the market.
In summary, it doesn't make sense to me for Acadia to delay NNZ-2591 for the purposes of undermining Neuren.
Considering the incredible results from 3 phase III studies and the reduced safety protocol now accepted by the FDA, it seems financially negligent for Acadia not to be proceeding full steam with NNZ-2591. So there must be a reason - we just don't know what it is...
Perhaps in their results call next month they'll announce they're now moving NNZ-2591 forward at top speed. If not, then it's a mystery why.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)